Patient-specific tumor neoantigen-Major Histocompatibility Complex class II complex (NeoAg-MHC II)

A patient-specific tumor neoantigen-MHC class II complex is a molecular assembly consisting of a unique peptide derived from a somatic mutation in a patient's tumor cells, bound to a Major Histocompatibility Complex (MHC) class II molecule. These complexes are primarily expressed on the surface of professional antigen-presenting cells (APCs) and, in some cases, tumor cells themselves. Their primary biological role is to present non-self tumor-specific peptides to CD4+ T-helper cells, which are crucial for orchestrating a robust and sustained anti-tumor immune response (Alspach et al., Nature 2019). In the context of immunotherapy, these complexes are the fundamental targets for personalized cancer vaccines and TCR-engineered T-cell therapies (Sahin et al., Nature 2017). By specifically targeting neoantigens, these therapies aim to minimize off-target effects on healthy tissues while maximizing the immune system's ability to recognize and eliminate malignant cells. The identification and selection of these complexes involve sophisticated genomic sequencing and bioinformatic algorithms to predict peptide-MHC binding affinity and immunogenicity (Ott et al., Nature 2017). Successful targeting of these complexes can lead to the expansion of neoantigen-specific T cell populations, providing long-term surveillance against tumor recurrence (Hu et al., Nature Reviews Cancer 2021).

Other names

Tumor-specific neoepitope-HLA class II complexPersonalized neoantigen-MHC IINeoepitope-MHC II complexNeoAg-HLA-II complex

Induction of a patient-specific immune response by presenting tumor-derived mutant peptides to CD4+ T cells, which facilitates the activation of cytotoxic CD8+ T cells and the formation of immunological memory against the tumor (Alspach et al., Nature 2019; Hu et al., Nature Reviews Cancer 2021).